The CX3CL1/CX3CR1 Reprograms Glucose Metabolism Through HIF-1 Pathway in Pancreatic Adenocarcinoma

被引：21

作者：

Ren, He ^{[1
]}

Zhao, Tiansuo ^{[1
]}

Sun, Junwei ^{[1
]}

Wang, Xiuchao ^{[1
]}

Liu, Jingcheng ^{[1
]}

Gao, Song ^{[1
]}

Yu, Ming ^{[1
]}

Hao, Jihui ^{[1
]}

机构：

[1] Tianjin Med Univ Canc Inst & Hosp, Dept Pancreat Canc, Key Lab Canc Prevent & Therapy, Tianjin 300060, Peoples R China

来源：

JOURNAL OF CELLULAR BIOCHEMISTRY | 2013年 / 114卷 / 11期

基金：

中国国家自然科学基金;

关键词：

CX3CL1; GLUCOSE METABOLISM; HYPOXIA-INDUCIBLE FACTOR-1; PANCREATIC ADENOCARCINOMA; CANCER-CELLS; HYPOXIA; UBIQUITINATION; ANGIOGENESIS; FRACTALKINE; EXPRESSION; MIGRATION; SURVIVAL;

D O I：

10.1002/jcb.24608

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

One of the hallmarks of cancer is revised glucose metabolism that promotes cell survival and proliferation. In pancreatic cancer, the regulatory mechanism of glucose metabolism remains to be elucidated. In this study, we found that CX3CR1 is expressed in pancreatic cancer cells lines. Exogenous or transfected CX3CL1 increased glucose uptake and lactate secretion. CX3CL1 stimulated HIF-1 expression through PI3K/Akt and MAPK pathways. Furthermore, knockdown of HIF-1 blocked CX3CL1-modified glucose metabolism in pancreatic adenocarcinoma cells. In conclusion, the CX3CL1/CX3CR1 reprograms glucose metabolism through HIF-1 pathway in pancreatic cancer cells. J. Cell. Biochem. 114: 2603-2611, 2013. (c) 2013 Wiley Periodicals, Inc.

引用

收藏

页码：2603 / 2611

页数：9

相关论文

共 26 条

[1] Dominant-negative hypoxia-inducible factor-1α reduces tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism [J].

Chen, J ;

Zhao, SJ ;

Nakada, K ;

Kuge, Y ;

Tamaki, N ;

Okada, F ;

Wang, JX ;

Shindo, M ;

Higashino, F ;

Takeda, K ;

Asaka, M ;

Katoh, H ;

Sugiyama, T ;

Hosokawa, M ;

Kobayashi, M .

AMERICAN JOURNAL OF PATHOLOGY, 2003, 162 (04) :1283-1291

[2] Brick by brick: metabolism and tumor cell growth [J].

DeBerardinis, Ralph J. ;

Sayed, Nabil ;

Ditsworth, Dara ;

Thompson, Craig B. .

CURRENT OPINION IN GENETICS & DEVELOPMENT, 2008, 18 (01) :54-61

[3] Ubiquitination of G Protein-Coupled Receptors: Functional Implications and Drug Discovery [J].

Dores, Michael R. ;

Trejo, JoAnn .

MOLECULAR PHARMACOLOGY, 2012, 82 (04) :563-570

[4] Inflammation and the development of pancreatic cancer [J].

Farrow, B ;

Evers, BM .

SURGICAL ONCOLOGY-OXFORD, 2002, 10 (04) :153-169

[5] Identification of the Chemokine CX3CL1 as a New Regulator of Malignant Cell Proliferation in Epithelial Ovarian Cancer [J].

Gaudin, Francoise ;

Nasreddine, Salam ;

Donnadieu, Anne-Claire ;

Emilie, Dominique ;

Combadiere, Christophe ;

Prevot, Sophie ;

Machelon, Veronique ;

Balabanian, Karl .

PLOS ONE, 2011, 6 (07)

[6] Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation [J].

Heiden, Matthew G. Vander ;

Cantley, Lewis C. ;

Thompson, Craig B. .

SCIENCE, 2009, 324 (5930) :1029-1033

[7] Identification and molecular characterization of fractalkine receptor CX(3)CR1, which mediates both leukocyte migration and adhesion [J].

Imai, T ;

Hieshima, K ;

Haskell, C ;

Baba, M ;

Nagira, M ;

Nishimura, M ;

Kakizaki, M ;

Takagi, S ;

Nomiyama, H ;

Schall, TJ ;

Yoshie, O .

CELL, 1997, 91 (04) :521-530

[8] Otto Warburg's contributions to current concepts of cancer metabolism [J].

Koppenol, Willem H. ;

Bounds, Patricia L. ;

Dang, Chi V. .

NATURE REVIEWS CANCER, 2011, 11 (05) :325-337

[9] Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. [J].

Koukourakis, MI ;

Giatromanolaki, A ;

Harris, AL ;

Sivridis, E .

CANCER RESEARCH, 2006, 66 (02) :632-637

[10] HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis:: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression [J].

Laughner, E ;

Taghavi, P ;

Chiles, K ;

Mahon, PC ;

Semenza, GL .

MOLECULAR AND CELLULAR BIOLOGY, 2001, 21 (12) :3995-4004